These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 33087441)

  • 1. Beta blockers versus calcium channel blockers for provocation of vasospastic angina after drug-eluting stent implantation: a multicentre prospective randomised trial.
    Sawano M; Katsuki T; Kitai T; Tamita K; Obunai K; Ikegami Y; Yamane T; Ueda I; Endo A; Maekawa Y; Kawamura A; Fukuda K; Kohsaka S
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33087441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis.
    Kuramitsu S; Ohya M; Shinozaki T; Otake H; Horie K; Kawamoto H; Yamanaka F; Natsuaki M; Shiomi H; Nakazawa G; Ando K; Kadota K; Saito S; Kimura T
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007822. PubMed ID: 31177822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL; Han YL; Zhang YJ; Ye F; Liu HW; Zhang JJ; Xu B; Jiang TM; Zhou YJ; Lv SZ
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1233-41. PubMed ID: 24239199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):E40-E55. PubMed ID: 31423723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative.
    Chandrasekhar J; Baber U; Sartori S; Stefanini GG; Sarin M; Vogel B; Farhan S; Camenzind E; Leon MB; Stone GW; Serruys PW; Wijns W; Steg PG; Weisz G; Chieffo A; Kastrati A; Windecker S; Morice MC; Smits PC; von Birgelen C; Mikhail GW; Itchhaporia D; Mehta L; Kim HS; Valgimigli M; Jeger RV; Kimura T; Galatius S; Kandzari D; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2018 Jan; 11(1):53-65. PubMed ID: 29301648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct drug-eluting stenting to reduce stent restenosis: a randomized comparison of direct stent implantation to conventional stenting with pre-dilation or provisional stenting in elective PCI patients.
    Remkes WS; Somi S; Roolvink V; Rasoul S; Ottervanger JP; Gosselink AT; Hoorntje JC; Dambrink JH; de Boer MJ; Suryapranata H; van 't Hof AW;
    JACC Cardiovasc Interv; 2014 Jul; 7(7):751-8. PubMed ID: 25060017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.
    van Houwelingen KG; van der Heijden LC; Lam MK; Kok MM; Löwik MM; Louwerenburg JW; Linssen GC; IJzerman MJ; Doggen CJ; von Birgelen C
    Heart Vessels; 2016 Nov; 31(11):1731-1739. PubMed ID: 26747438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
    Sakamoto T; Ogawa H; Nakao K; Hokimoto S; Tsujita K; Koide S; Yamamoto N; Shimomura H; Matsumura T; Oshima S; Kikuta K; Oka H; Kimura K; Matsui K;
    J Cardiol; 2016 Apr; 67(4):371-7. PubMed ID: 26254019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between stent thrombosis and calcium channel blocker after drug-eluting stent implantation: Kumamoto Intervention Conference Study (KICS) registry.
    Nagano M; Hokimoto S; Nakao K; Kaikita K; Akasaka T; Ogawa H;
    J Cardiol; 2015 Oct; 66(4):333-40. PubMed ID: 25572022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
    Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
    EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy comparison of primary percutaneous coronary intervention by drug-coated balloon angioplasty or drug-eluting stenting in acute myocardial infarction patients with de novo coronary lesions].
    Zhang DP; Wang LF; Liu Y; Li KB; Xu L; Li WM; Ni ZH; Xia K; Zhang ZY; Yang XC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):600-607. PubMed ID: 32842271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.